The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by
patients who have diastolic heart failure, or heart failure with preserved ejection fraction
(HFpEF).
Inclusion Criteria:
- Diagnosed with HFpEF within a 6-month period
- New York Heart Association (NYHA) Classification II-III HF
- Have left ventricular ejection fraction (EF) ≥ 50% documented by an echocardiogram
- Have a telephone or reliable phone contact
- Have their own means of transportation to the study site
Exclusion Criteria:
- Acute coronary syndrome in the past 12 weeks
- Significant valvular heart disease
- Severe cardiac fibrosis (galectin-3 level > 26 ng/ml)
- Constrictive pericardium
- Pulmonary fibrosis
- Congenital heart disease
- Hypertrophic or infiltrative cardiomyopathy
- Heart transplant
- Left ventricular assist device
- Heart failure (HF) associated hospital admission or emergency room visit within past
30 days
- Recent percutaneous coronary intervention
- Significant renal and/or hepatic dysfunction
- Severe cognitive impairment
- Consumption of any CoQ10 (ubiquinol) or D-ribose supplements
